All In Biotech

Drug Trial Radar · NCT00334386

Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.

Multicentre, Multinational, Parallel, Randomised, Double Blind Clinical Trial, to Evaluate the Non-inferiority of PR Torasemide Versus IR Torasemide in Patients With Mild or Moderate Arterial Hypertension.

Last checked: Nov 20, 2026Latest source record: Mar 6, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 388 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

388

Actual

Start

Apr 2005

Primary completion

Not stated

Study completion Feb 2006

Sponsor

Lead sponsor
Ferrer Internacional S.A.Industry
Sponsor type
Industry
First posted
Jun 7, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective:To demonstrate the no-inferiority in efficacy of treatment with Torsemide-PR in relation to Torsemide-IR in patients with mild and/or moderate hypertension. Secondary objectives: To evaluate the safety and tolerability of Torsemide-PR.

Conditions

  • Hypertension

Interventions

  • Torasemide Prolonged Release (loop diuretic)Drug

  • Torasemide Immediate Release (loop diuretic)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in mm Hg between the mean diastolic blood pressure (DBP) values the baseline period and the values at the end of the treatment period.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.